Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 8:18:683-698.
doi: 10.2147/TCRM.S263832. eCollection 2022.

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma

Manuela Tiako Meyo  1   2 , Jeanne Chen  1   2 , Francois Goldwasser  1   2 , Laure Hirsch  1   2 , Olivier Huillard  1   2
Affiliations
Review

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma

Manuela Tiako Meyo et al. Ther Clin Risk Manag. .

Abstract

Until recently, the approved first-line treatment for metastatic RCC (mRCC) consisted of tyrosine kinase inhibitors (TKI) targeting the vascular endothelial growth factor receptors (VEGFR) monotherapy. The landscape of first-line treatment has been transformed in the last few years with the advent of immune checkpoint inhibitors (ICI) or VEGFR TKI plus ICI combinations. This article focuses on the profile of one of these ICI plus VEGFR TKI combination, avelumab plus axitinib. We detail the characteristics of each drug separately, and then we explore the rationale for their association, its efficacy and the resulting toxicity. Finally, we examine the factors associated with avelumab plus axitinib outcomes, and their impact on therapeutic strategy.

Keywords: avelumab; axitinib; immune checkpoint inhibitor; pharmacology; renal cell carcinoma; vascular endothelial growth factor.

PubMed Disclaimer

Conflict of interest statement

Pr. Goldwasser reports grants and personal fees from BAXTER, and personal fees from FRESENIUS. KABI, and NUTRICIA, outside the submitted work. Dr. Huillard reports personal fees from BAYER, SANOFI, MSD, BMS, IPSEN, PFIZER, EISAI, JANSSEN, and ASTRA ZENECA, outside the submitted work. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Complementary mechanisms of action of immune checkpoint inhibitors and Vascular endothelial growth factor pathway inhibitors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708 - DOI - PubMed
    1. Rini BI, Dorff TB, Elson P, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, Phase 2 trial. Lancet Oncol. 2016;17(9):1317–1324. doi:10.1016/S1470-2045(16)30196-6 - DOI - PMC - PubMed
    1. Marchioni M, Bandini M, Pompe RS, et al. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. Int Urol Nephrol. 2017;49(12):2143–2149. doi:10.1007/s11255-017-1703-y - DOI - PubMed
    1. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–731. doi:10.1056/NEJMoa1303989 - DOI - PubMed
    1. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–3590. doi:10.1200/JCO.2008.20.1293 - DOI - PMC - PubMed